Infinimmune has secured $75 million in Series A funding, marking its first major institutional round. This capital infusion will accelerate the development of its human-derived antibody pipeline targeting atopic dermatitis and other inflammatory diseases. The company plans to advance its lead drug candidate, IFM-2427, into clinical trials and expand its research team.